Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients : Correlation With FDG-PET/CT and Anatomopathological Results

NCT01420146 is registered in ClinicalTrials.gov with Jules Bordet Institute as lead sponsor.

NCT NCT01420146
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01420146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients : Correlation With FDG-PET/CT and Anatomopathological Results
Lead sponsor
Jules Bordet Institute
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2011
Completion date
September 30, 2015
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, her2 positive carcinoma of breast, secondary